Silvia Chiroli
Zug, ZG, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG.
Journal: BMJ open
Published: January 31, 2023
Efgartigimod improved health-related quality of life in generalized myasthenia gravis: results from a randomized, double-blind, placebo-controlled, phase 3 study (ADAPT).
Journal: Journal of neurology
Published: August 25, 2022
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.
Journal: Applied health economics and health policy
Published: June 07, 2019
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Journal: Current medical research and opinion
Published: August 09, 2018
Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
Journal: Journal of medical economics
Published: July 23, 2013
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.
Journal: BMC nephrology
Published: December 05, 2012
Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: a retrospective cohort study.
Journal: BMC nephrology
Published: April 20, 2012
A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries.
Journal: Applied health economics and health policy
Published: January 25, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026